Kurse werden geladen...
Anzeige
Prognose
| Kaufen | 4 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening of the Nasdaq CM.» Mehr auf globenewswire.com
Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset EVX-01. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).» Mehr auf globenewswire.com
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting
COPENHAGEN, Denmark, April 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data underscoring the ability of cancer vaccine EVX-01 to drive a targeted and robust immune response. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | Dez. 2024 | |
|---|---|---|
| Umsatz | 117,24k | 76,10% |
| Bruttoeinkommen | 117,24k | 76,10% |
| Nettoeinkommen | −3,49 Mio | 15,45% |
| EBITDA | −5,39 Mio | 39,69% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 2,32 Mio€ |
Anzahl Aktien | 1,40 Mio |
52 Wochen-Hoch/Tief | 18,30€ - 1,06€ |
| Dividenden | Nein |
Beta | -0,23 |
KGV (PE Ratio) | −0,20 |
KGWV (PEG Ratio) | 0,01 |
KBV (PB Ratio) | −1,30 |
KUV (PS Ratio) | 0,79 |
Anzeige
Unternehmensprofil
| Name | EVAXION BIOTECH SP.ADS/50 ADR |
| CEO | Christian Kanstrup M.Sc. |
| Mitarbeiter | 46 |
Assets entdecken
Shareholder von EVAXION BIOTECH SP.ADS/50 ADR investieren auch in folgende Assets
